Picture of Zai Lab logo

ZLAB — Zai Lab News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Brief: Zai Lab Unveils Promising Phase 1 Data for DLL3 ADC; Launches Global Phase 3 Trial

Oct 24 (Reuters) - Zai Lab Ltd 9688.HK:

ZAI LAB ANNOUNCES UPDATED PHASE 1 DATA FOR ZOCILURTATUG PELITECAN (FORMERLY ZL-1310), DEMONSTRATING POTENTIAL AS A FIRST-IN-CLASS/BEST-IN-CLASS DLL3-TARGETED ADC FOR SMALL CELL LUNG CANCER, AND INITIATION OF GLOBAL PHASE 3 REGISTRATIONAL STUDY

ZAI LAB LTD - GLOBAL PHASE 3 TRIAL INITIATED FOR SECOND-LINE SCLC

ZAI LAB LTD: FIRST-LINE SCLC & NEUROENDOCRINE CARCINOMA PROGRAMS ADVANCING TOWARD REGISTRATIONAL PHASE IN 2026

Source text: ID:nBw3sDtg1a

Further company coverage: 9688.HK

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Zai Lab

See all news